Clinical Development Strategy

Neuren’s strategy is to undertake clinical trials for acute conditions, which are generally shorter and less expensive than those for chronic conditions. This strategy provides the most cost-effective means of increasing shareholder value while controlling risk.

Neuren decides which targets to pursue and which compounds to develop only after consideration of the cost and complexity of trials, the ease with which results can be validated, and assessment of market need and commercial opportunity.